Physician-scientist Ingo Mellinghoff studies signal transduction alterations in primary brain tumors at Memorial Sloan Kettering Cancer Center.

Our laboratory focuses on the study of molecular pathways that regulate brain tumor growth. Our long-term goal is to develop therapeutic paradigms that target specific properties of primary brain tumors, including genetic alterations in cancer signaling pathways, unique aspects of brain tumor metabolism, or interactions of brain tumor cells with their brain microenvironment. Our studies in experimental brain tumor models are closely linked to the evaluation of novel agents in early-phase clinical trials.

Read more on the Memorial Sloan Kettering Cancer Center website.